U.S. markets open in 5 hours 5 minutes
  • S&P Futures

    3,921.25
    -1.25 (-0.03%)
     
  • Dow Futures

    31,963.00
    +47.00 (+0.15%)
     
  • Nasdaq Futures

    13,241.75
    -60.25 (-0.45%)
     
  • Russell 2000 Futures

    2,298.90
    +13.80 (+0.60%)
     
  • Crude Oil

    63.76
    +0.54 (+0.85%)
     
  • Gold

    1,790.90
    -7.00 (-0.39%)
     
  • Silver

    28.02
    +0.09 (+0.33%)
     
  • EUR/USD

    1.2216
    +0.0048 (+0.39%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    22.11
    -1.00 (-4.33%)
     
  • GBP/USD

    1.4168
    +0.0027 (+0.19%)
     
  • USD/JPY

    106.1400
    +0.2580 (+0.24%)
     
  • BTC-USD

    49,183.15
    -1,473.71 (-2.91%)
     
  • CMC Crypto 200

    982.40
    -12.26 (-1.23%)
     
  • FTSE 100

    6,678.19
    +19.22 (+0.29%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020

  • Oops!
    Something went wrong.
    Please try again later.
Corbus Pharmaceuticals Holdings, Inc.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET

Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its third quarter financial results on Tuesday, November 10. Corbus management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, who will be joined by additional members of the Corbus management team. Interested participants and investors may access the conference call by dialing (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com and will be archived for 90 days Following the event.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.

For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Contacts:

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com